Bharat Parenterals (BPL) is a 1992-founded, Vadodara (Gujarat) manufacturer of finished dosage forms — small-volume parenterals, powder-for-injection, tablets, capsules, creams, ointments, gels and oral suspensions — sold across anaesthetics, antibiotics, CNS, anti-malarial, anti-retroviral and anti-TB therapy areas to 40+ export markets and domestic institutional tenders. Its 55.9%-owned subsidiary Innoxel Lifesciences is a USFDA- and EU-GMP-cleared CDMO making complex/specialty injectables (liposomal, extended-release, oncology) for regulated US/EU partners under out-licensing and CMO/CDO arrangements. Wholly-owned Varenyam Healthcare markets branded institutional generics (anaesthesia, critical care, pain) through its own field force to hospitals across India, while wholly-owned Varenyam Bio Lifesciences is building an EU-GMP-targeted complex-injectables facility in Vadodara aimed at other regulated (SRA/PICs) markets.
Business segments
BPL Standalone Innoxel Lifesciences Varenyam Healthcare Varenyam Bio Lifesciences
Key products & brands: Small volume parenterals, Powder for injection, Tablets, Capsules, Creams, ointments, gels, Oral suspensions/liquids, Sugmadex (Sugammadex), Termiva (Mephentermine), Adhestop (Heparin Sodium), Atrabloc (Atracurium Besylate), Zocifix (Pentazocine), Sevovar (Sevoflurane USP), Rocurofix (Rocuronium), Varxon (Ceftriaxone), Varmol (Paracetamol), Remishot (Remifentanil)
Key data
Manufacturing facility (BPL standalone)
300,000 sq.ft. in Vadodara, Gujarat — 3 dedicated production blocks (General, Beta-Lactam, Cephalosporin)
Installed capacity (FY26, mn units/yr)
General block: Tablets 1,845 · Capsules 1,120 · Injections 103 · Liquids 46 · Powder 27; Beta-Lactam: Tablet/Capsule 900/900, Dry Syrup 46, Powder for Injection 45; Cephalosporin: Tablet/Capsule 660/518, Dry Syrup 51, Powder for Injection 45
Capacity utilization (FY26)
General block 48.5% · Beta-Lactam 21% · Cephalosporin 24.3%
Export presence
40+ countries
Product registrations/filings
350+ cumulative filings; 48 new registrations and 214 dossiers submitted in FY26
Standalone manpower
500+ technical and non-technical staff
Innoxel manufacturing infrastructure
Vadodara facility with 2 blocks (General injectables/oral liquids + Oncology/potent injectables); 4 production lines validated cumulatively
Varenyam Healthcare distribution network
211 medical representatives covering 7,500+ hospitals across 26 states via 10 owned depots and 800+ channel partners
Varenyam Healthcare brand portfolio
45 active brands
Varenyam Bio Lifesciences facility (under development)
Vadodara — planned 2 oncology lines + 1 injectable (vial with Lyo) line + 1 oral-liquid line
Headquarters
Vadodara, Gujarat